Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the therapeutic efficacy and safety of DA-9701 with domperidone in patients with Parkinson's disease

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Domperidone

Criteria

Inclusion Criteria:

• subjects diagnosed with spontaneous parkinsonism by the United Kingdom(UK) Parkinson's Disease Society Brain Bank criteria

• subjects who are able to explain symptoms they experience and to complete relevant assessment and exams including questionaires

• subjects who understand the purpose and protocols of the study and agree to participate on the study

Exclusion Criteria:

• subjects who experience psychiatrical disorders such as cognitive or behavioral disorders

• subjects who are on prokinetics or who are unable to cease such medication

• subjects who present neurological disorders which influence gastrointestinal mobility

• subjects who present gastrointestinal conditions which influence gastrointestinal mobility

• subjects with a history of gastrectomy or colectomy

• subjects who are unable to receive and complete the course of medication due to other metabolic disorders

• subjects diagnosed with parkinson plus syndrome

• subjects who are unable to undergo MRI scan for safety reasons due to claustrophobia or certain devices such as cardiac pacemakers or aneurysm clips